AIM
SNOA icon

Acrospire Investment Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

Acrospire Investment Management’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$2K – 2510
2017
Q1 		$2K Sell
1
-16
-94% -$18.6K ﹤0.01% 2120
2016
Q4 		$15K Buy
+17
New +$14.1K 0.01% 1858

Other funds holding SNOA

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acrospire Investment Management's SNOA Position: Q2 2017 in Review

Acrospire Investment Management sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2017, closing a stake of 1 share — an estimated $2K sold.

Acrospire Investment Management first reported a position in SNOA in Q4 2016 and held it in 2 quarters. The position peaked at $15K in Q4 2016. 16 funds tracked by Wall St. Rank hold SNOA as of Q2 2017.

  • Acrospire Investment Management reported no remaining Sonoma Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 Sonoma Pharmaceuticals share in Q2 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in Sonoma Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Sonoma Pharmaceuticals position peaked at $15K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.